Inc.;Acceleron Pharma, Inc.;Acceleron Pharma;Ludwig Institute for Cancer Research Ltd.
发明人:
Grinberg, Asya,Seehra, Jasbir,Kumar, Ravindra,Pietras, Kristian,Knopf, John,Pearsall, Robert Scott
申请号：
AU2009241755
公开号：
AU2009241755B2
申请日:
2009.05.01
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALKl) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALKl may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALKl and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction
